Your browser doesn't support javascript.
loading
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo, Courtney D; Rausch, Caitlin R; Benton, Christopher; Kadia, Tapan; Jain, Nitin; Pemmaraju, Naveen; Daver, Naval; Covert, Wendy; Marx, Kayleigh R; Mace, Morgan; Jabbour, Elias; Cortes, Jorge; Garcia-Manero, Guillermo; Ravandi, Farhad; Bhalla, Kapil N; Kantarjian, Hagop; Konopleva, Marina.
Affiliation
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rausch CR; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Benton C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Covert W; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Marx KR; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Mace M; Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bhalla KN; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Am J Hematol ; 93(3): 401-407, 2018 03.
Article in En | MEDLINE | ID: mdl-29218851
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute / Antineoplastic Combined Chemotherapy Protocols / Salvage Therapy / Proto-Oncogene Proteins c-bcl-2 / Molecular Targeted Therapy / Neoplasm Proteins Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Am J Hematol Year: 2018 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute / Antineoplastic Combined Chemotherapy Protocols / Salvage Therapy / Proto-Oncogene Proteins c-bcl-2 / Molecular Targeted Therapy / Neoplasm Proteins Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Am J Hematol Year: 2018 Document type: Article